Dr. Xingyu Chen | Cancer Biology | Young Scientist Award
Research Bioinformatician | Cedars-Sinai Medical Center | United States
Dr. Xingyu Chen is a research bioinformatician and computational oncologist specializing in sex chromosome genomics, cancer immunology, and precision medicine. His work has revealed the Loss of the Y Chromosome (LOY) as a causal driver of cancer immune evasion in men, demonstrating its role in tumor progression, immune dysfunction, and therapy resistance. He pioneered the development of the world’s first Sex Chromosome-Aware Genomic Large Language Model, integrating AI with genomic data to enhance cancer diagnostics and guide precision therapies. His research combines multi-omics analysis, single-cell and spatial transcriptomics, and deep-learning models to uncover mechanisms of tumor evolution, T-cell exhaustion, and sex-specific cancer vulnerabilities. Chen has contributed to high-impact publications in journals such as Nature, Oncogene, and International Journal of Molecular Sciences, with 800 citations, an h-index of 15, and multiple first/co-first author contributions, reflecting his influence in the field. His work extends to translational applications, including LOY-informed cellular therapies and radiogenomic predictive algorithms for bladder cancer, leading to patentable innovations. He has also mentored trainees, co-supervised projects, and collaborated with international institutions to advance integrative cancer genomics and AI-driven therapeutics. Overall, his research advances the understanding of male-biased cancer mechanisms and supports the development of innovative diagnostic and therapeutic strategies, bridging fundamental biology, computational modeling, and clinical applications to improve outcomes for men with cancer.
Profile: Google Scholar
Featured Publications
Abdel-Hafiz, H. A., Schafer, J. M., Chen, X., Xiao, T., Gauntner, T. D., Li, Z., … et al. (2023). Y chromosome loss in cancer drives growth by evasion of adaptive immunity. Nature, 619(7970), 624–631.
Jin, Y., Wang, Z., He, D., Zhu, Y., Chen, X., & Cao, K. (2021). Identification of novel subtypes based on ssGSEA in immune‐related prognostic signature for tongue squamous cell carcinoma. Cancer Medicine, 10(23), 8693–8707.